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Background: Late Onset Tay- Sachs disease (LOTS) is a rare neurodegenerative lysosomal storage disease which
results from mutations in the gene encoding the α subunit (HEXA) of β-hexosaminidase enzyme (HexA). At the
present time, no effective treatment exists for LOTS and other neurodegenerative diseases involving the central
nerve system (CNS). Pyrimethamine (PMT) was previously shown to act as a HexA chaperone in human fibroblasts
in vitro carrying some (e.g., αG269S), but not all LOTS-related mutations. The present study assessed the effect of
cyclic, low dose and long term pyrimethamine treatment on HexA in subjects with LOTS.
Methods: In an open label trial in 4 LOTS patients, PMT was initiated at an average daily dose of ~2.7 mg and
administered cyclically guided by blood lymphocyte HexA activity for a mean duration of 82.8 (±22.5; SD) weeks
(~1.5 year).
Results: HexA activity rose in all subjects, with a mean peak increase of 2.24 folds (±0.52; SD) over baseline activity
(range 1.87-3). The mean treatment time required to attain this peak was of 15.7 (±4.8; SD) weeks. Following
increase in activity, HexA gradually declined with the continued use of PMT, which was then stopped, resulting in
the return of HexA activity to baseline. A second cycle of PMT treatment was then initiated, resulting again in an
increase in HexA activity. Three of the patients experienced a measurable neuropsychiatric deterioration whereas
one subject remained entirely stable.
Conclusions: Cyclic low dose of PMT can increase HexA activity in LOTS patients. However, the observed increase
is repeatedly transient and not associated with discernible beneficial neurological or psychiatric effects.
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Late Onset Tay Sachs disease (LOTS) is a rare variant of
Tay Sachs disease (TSD), that results from mutations in
the gene encoding the α subunit of β-hexosaminidase A
(HexA). HexA is a lysosomal enzyme which degrades
the ganglioside GM2 [1], thus allowing normal GM2
turnoover. Tay-Sachs disease evolves due to accumula-
tion of GM2 in neural cells in the central nervous sys-
tem secondary to decreased HexA activity. The disease* Correspondence: naftalis@tlvmc.gov.il
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unless otherwise stated.is clinically heterogeneous: in the most severe form, in-
fantile TSD, severe Hex A malfunction leaving residual
activity of just ~ <0.5% of the normal level leads to rapid
neurodegeneration, culminating in infant mortality. In
contrast, the LOTS variant occurs in individuals harboring
compound heterozygote or mild homozygote α subunit
gene mutation and is linked to higher residual HexA cata-
lytic efficacy amounting to 2-5% of normal activity. This
results in a more gradual course of neurodegeneration as
evidenced by delayed onset and more gradual decline in
motor, cerebral and spinocerebellar function. Additionally,
LOTS is typically associated with psychiatric manifestations
such as depression, bipolar disorder and psychosis [2].
Based on the correlation between residual HexA activityThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tions, it has been suggested that 10% of the normal HexA
activity could be sufficient to avoid the development of a
clinical disorder [3]. No clinically effective treatment for
LOTS and other lysosomal diseases involving the central
nerve system presently exists. Since any such putative mode
of therapy requires access to the central nervous system
(CNS), the use of small molecules functioning as pharma-
cological chaperones, which can potentially stabilize
the native folding of the protein despite its anomalous
conformation, thus preventing aggregation and restoring
enzyme activity, appears attractive. Mahuran’s group pio-
neered the application of this approach in LOTS and
tested the possibility that pharmacological chaperones can
augment HexA activity in cells carrying a variety of LOTS-
related mutations in vitro [4]. Following extensive screen-
ing of candidate molecules, these investigators identified
pyrimethamine (PMT), an FDA approved anti-marial/
anti-toxoplasmosis agent already in use in humans and is
capable of entering the central nervous system (CNS)
[5-8], as an enhancer of HexA activity in vitro in human
fibroblasts carrying some (e.g., αG269S), but not all LOTS
related mutations [9]. We have previously reported that
PMT administered in a dose escalating protocol was
able to enhance HexA activity in 9 patients LOTS patients
who were compound heterozygotes carrying the αG269S/
c.1278insTACT mutations. This may have been associated
with some subtle clinical benefits. Similar biochemical
effects were reported by Clarke et al. [10,11]. However,
our previous results also indicated that the effect of PMT
wanes and, at times, is even reversed with an increas-
ing dose of PMT and the passage of treatment time.
The present brief report, therefore, summarizes a follow
up study of the biochemical effect of PMT, using a modi-
fied protocol. Here we tested the effect of cyclic low dose
PMT on HexA activity in 4 out of the 9 LOTS patients in-
cluded our previous study.
Methods
Patient recruitment and study design
Inclusion criteria were as those applied in our previous study
[10], namely, genetically and clinically confirmed diagnosis
of LOTS (compound heterozygotes carrying the αG269S/
c.1278insTACT mutation); lack of contraindications for
the use of PMT and patient’s interest in close surveillance at
the study center. Exclusion criteria for participation in this
study were any known sensitivity to PMT, the presence of
known or convulsive disease, and any serious medical illness
such as cardiac disease, hematologic abnormality, or malab-
sorbtion [10]. In all, 4 out of the 9 with LOTS participating
in our previous study expressed interest to enroll into this
modified continuation protocol and were all found eligible.
Subjects were assessed every 4–8 weeks apart by a
multidisciplinary team including a neurologist, psychiatristand a specialist in internal medicine. As part of this
assessment, HexA activity was also assessed every 4–8
weeks, at each of the evaluation points. PMT was pre-
scribed at a dose of 6.25 mg taken orally 3 times a week
(~2.7 mg/day). This dose was chosen according to the re-
sults obtained from our previous study, in which PMT’s
effect on HexA activity and tolerability was examined in 9
patients at a dose range reaching up to 75 mg PMT/day.
In that former study, PMT at a dose of 6.25 mg taken or-
ally 3 times a week was effective in increasing HexA activ-
ity, yet it induced no side effects [10]. In the present study
we sought to evaluate the long term effect of the low dose
of PMT and maintained therapy as long as no appreciable
clinical or biochemical side effects were noted and HexA
activity did not decline by more than 25% as compared to
the pre-treatment level. Folic acid (5 mg/day) was added
with the initiation of PMT. Mean duration of the active
PMT treatment was 82.8 (±22.5) weeks.
The primary outcome measures were the changes in
HexA activity in peripheral lymphocytes as well as the
safety and tolerability of PMT therapy in LOTS patients in
a long term, low dose protocol. The secondary outcome
measures included potential changes in neurological and
psychomotor status of PMT-treated LOTS patients as de-
fined by the itemized description below.
The study was approved by the institutional IRB as well as
by the Israeli Ministry of Health Review Board for clinical
trials and was conducted in accordance with the Declaration
of Helsinki. Written informed consent was obtained from
each individual participating in the study.
Neurological and psychiatric evaluation
Disability was assessed by the Standard ambulation index
[12] and the Amyotrophic Lateral Sclerosis Functional Rat-
ing Scale (ALSFRS) [13]. The “up & go” test was used to
measure mobility. Handgrip strength was assessed by
means of dynamometry in both hands. Manual muscle
strength was assessed using the modified Medical Research
Council (MRC) scale. The assessed muscle functions in-
cluded shoulder abduction, elbow flexion and extension,
finger extension, hip flexion, knee extension and flexion
and foot dorsiflexion. Muscle strength was rated for right
and left side and expressed as means of the two sides. Gait
and balance were assessed by the Tinetti Gait and Balance
Scale [14], and the Modified Falls Efficacy Scale [15].
Psychiatric evaluation was carried out by patient interview
on each visit by the same psychiatrist. Diagnosis was made
according DSM IV-R criteria. The Hamilton questionnaire
(HAM-21) was used for depression rating and the PANSS
questionnaire was used for the evaluation of psychosis.
HexA activity
Lymphocyte HexA enzymatic activity was determined with
4-methylumbelliferyl-6-sulfo-N-acetyl-ß-D-glucosaminide
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[16]. In brief, cell extracts were prepared from whole blood
on the day of blood collection using standard methods and
stored in aliquots at −20°C. To determine HexA activity,
4 μg of lymphocyte extract protein were incubated with
MUGS (0.7 mM; Melford Laboratories, Suffolk, UK) in a
50 mM citrate buffer (pH 4.5; 37°C) over 1.5 hour. Fluores-
cence of the liberated 4-methylumbelliferone was mea-
sured by Synergy 2 fluorometer ((BioTek Instruments, Inc
Winooski, US; excitation 335 nm, emission 442 nm) and
normalized for protein content [17]. To minimize inter-
assay variations, each determination throughout the study
also included extracts from the baseline sample and at least
one additional sample from the intervention period. As
variations in the ratio between this “historical” and baseline
activity on repeat measurements did not exceed ±/−10%,
assessment of the current (treatment) sample relative to
baseline activity for each sample could be safely made
within the same assay. Extracts were stable in terms of en-
zyme activity for at least one year. Because the study lasted
for ~1.5 years, new extracts were prepared and compared
with the original baseline, so as to form a credibly stable
extract for continued comparative assessment. Calculated
intra-assay imprecision was 10.5% and inter-assay im-
precision was 26%. Biological variation in heterozygotes
was 2.1%.Statistical analysis
All endpoints and data were summarized using descrip-
tive statistics (mean values with standard deviations) and
non-parametric t-test using SPSS. HexA activity was cal-
culated and presented as percent change from baseline.Results
Baseline clinical assessment
Baseline demographic and clinical characteristics are pre-
sented in Table 1. Mean patient age was 28.6 (±5.3; [SD])
years and the mean duration of the pre-trial symptomatic
disease was 16.4 (±3.8; [SD]) years. Mean age of first clin-
ical sign was 12.3 (±3.2 [SD]). There was a considerable
variability in the severity of the neurological impairment






1 Man 34 15 Depression, hypersom
2 Man 21 10 Attention deficit
3 Man 29 15 Psychotic episodes
4 Man 30 9 Speech problemsEffects of pyrimethamine on HexA activity
Mean baseline HexA activity of study subjects was
72.1nmole/mg protein/hour (20.1 ± SD) (range: 48.3 to
92.1 nmol/mg protein/hour). When “normalized” in re-
lation to activity in unaffected normal human subjects,
this amounted to ~ 1.1% of the activity determined in
non-carrier, healthy subjects (±0.3%; [SD]; [range: 0.7%
to 1.3%); (Table 2).
PMT increased peripheral lymphocyte HexA activity
in all 4 study subjects with a mean peak increase of 2.24
(±0.52; [SD] folds over baseline; (range: 1.87-3). Hence,
while statistically significant, this achieved peak activity
equaled, on the average, to just ~ 2.2 % (±0.3%; [SD]) of
the normal activity in unaffected healthy subjects.
Figure 1 depicts individual HexA activity throughout
the study period, as a function of treatment period and
dose. As can be seen, an increase in HexA activity was
induced by PMT at a dose of 6.25 mg three times a week
in all study subjects. The effect of PMT treatment ap-
peared biphasic: an initial increase in HexA activity
followed by a second phase of decline and inhibition of
HexA activity, which was resolved by discontinuation of
PMT treatment. Mean duration of a cycle was 33.4
(±15.1 SD) weeks (range: 17–52 weeks). Following drug
withdrawal, once HexA activity returned to its baseline
level, a second cycle of PMT was initiated and resulted
again in enhancement of HexA activity followed again
by a decline, quite reminiscent of the reduction in activ-
ity already observed with continuous treatment in our
previous study [10]. Mean time to the first or second ac-
tivity peak was 15.7 (±4.8; [SD]; range: 14.7-22 weeks).
Mean time from the observed activity peak to an appre-
ciable decrease in activity was 16.7 (±11.7 [SD]; range:
3.8-36.7) weeks. There was no differences between “time
to peak” and “time to decrease” (P = 0.84), but this
reflected a very large inter-patient variability, particularly
in the rate at which the inhibitory effect/loss of effect
evolved.
Neuropsychiatric outcome
In general, there was large variability among the re-
peated assessments for all tests, which, in our opinion,
was highly dependent on concomitant fluctuation ingroup
osis Current treatment Affected family
members




Olanzapine, Lithium One sister
Olanzapine, Duloxetine None




(% of wild type*)
Peak HexA activity
(% of wild type*)
Peak increase in HexA activity
(fold Increase) relative to to baseline
1 92.1 1.3 2.5 1.87
2 84.8 1.2 2.5 2.1
3 63.3 0.9 1.8 2
4 48.3 0.7 2.1 3
HexA activity in lymphocyte was determined using MUGS as an artificial substrate as described in the Methods. [% of wild type*] refers to mean activity in
lymphocyte preparation from unaffected healthy subjects (“wild type”): 6900 ± 996 nmol/mg protein/hour (n = 3). Relative change in activity refers to fold change
relative to baseline, where baseline activity or activity unchanged from baseline is referred to as 1 (no change), 2 fold describes doubling, 3 fold refers to
tripling, etc.).
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line and final visit showed no improvement in any of the
study subjects. Only one subject enjoyed a crudely stable
neurological state (case number 2). The other three pa-
tients experienced a variable, albeit clear neurological de-
terioration. In one subject (case number 3) all categories
of the neurologic assessment were stable with the excep-
tion of a worsening in dysarthria, which was also the main
presenting symptom of this patient. The two remaining
patients, (cases 1 and 4) experienced continuous deteri-
oration. Patient 1 had a gradual reduction in both
hand grip strength and manual muscle strength, along
with worsening of balance and gait ability as assessed by
the Tinetti balance & gait scores. Patient 3 experienced aFigure 1 The continuous relation between HexA activity (solid line) and PM
presented in relation to the baseline measurements, determined repeatedlreduction in hand grip strength and manual muscle
strength along with worsening of performance in the
up & go test, the Tinetti balance & gait scores and the
falls efficacy assessment.
Adverse events
The lower doses of PMT were well-tolerated and none of
the subjects experienced significant side-effects. There was
no hematological or clinical evidence of folate deficiency.
Discussion
In two previous reports (10, 11), including one from our
group, it appeared that PMT could increase HexA activ-
ity in LOTS patients, thus raising some hope that thisT treatment (dashed line), as a function of time. HexA activity is
y with each measurement throughout the study.
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regarding PMT in LOTS in our first report, since we wit-
nessed that following an initial rise in HexA, levels declined.
In an attempt to avoid this secondary decline, which ap-
peared both/either time and/or dose depended, we de-
signed this present smaller study, using lower doses and a
cyclic mode of therapy. The main finding in this study is
that long term (~1.57 year) cyclic low dose PMT treat-
ment had a biphasic, effect on HexA activity with initial
enhancement followed by a second phase of inhibition of
activity. However, these effects on HexA activity were
somewhat variable in magnitude and duration and were
not associated with discernible clinical benefits.
The increase attained by cyclic treatment PMT on
HexA in LOTS patient was small to moderate, with an
average rise of ~2 fold over baseline activity, reflecting a
broad range of variability (1.8-3fold increase). This effect
still falls short of reaching the theoretically desirable in-
crease in HexA to “10% of normal HexA”, above which
a disease-free phenotype has been documented despite
the presence of LOTS mutations [2,3]. These modest re-
sults are nevertheless in general agreement with the
in vitro study by Megawa et al. [9], which demonstrated
that PMT can function as an effective pharmacological
chaperone for several α- and β-mutants affecting Hex A:
some, but not for all of HEXA and HEXB mutants
showed a 2–3 fold increase in HexA activity in the pres-
ence of PMT. In patients carrying the G269S mutation,
such as also present in all our patients, a 2 fold enhance-
ment in HexA activity was observed. While our results
in living subjects with LOTS are unfortunately disap-
pointing, they are nevertheless useful to students in the
field to prompt further the search for alternative mole-
cules or treatment protocols.
Several aspects of the present trial outcome should be
particularly noted. First, the increase in HexA activity
was time dependent, although the time required to
achieve the maximal response varied considerably
among the study subjects. Because the same dose was
used in all subjects, it would be difficult to establish
whether these differences reflect variation in the HexA’s
sensitivity to PMT or to differences related to the drug’s
kinetics. In referring to drug kinetics, however, we note
that the peak HexA activity achieved with the low dose
of PMT used in the present study was not appreciably
different and in fact appears somewhat higher than that
achieved by us in our previous study (2.2 fold in this
study; 1.78 fold in the previous study), in which much
higher doses (up reaching 75 mg/day) were used [10].
This would suggest that a simple correlation between
PMT levels and lymphocyte HexA activity in LOTS is
highly unlikely. Second, even a very low dose of PMT
such as used in the present report invariably induced,
with the passage of time, a secondary decline in HexAactivity. Hence, long term treatment with PMT, even at
a low dose, eventually resulted in inhibition of HexA ac-
tivity. Furthermore, discontinuation of PMT reversed
the inhibition of HexA activity. Third, despite the ob-
served PMT-induced clear increase in HexA activity in
each of the 4 of the treated LOTS patients, and despite
the fact that we were able to maintain LOTS patients on
cyclic PMT treatment for up to ~1.5 year in terms of
biochemical and clinical tolerability, no obvious clinical
effect was observed. Three out of the four subjects in
this trial experienced a continuous neurological decline.
Only the youngest patient with the shortest period of
disease presentation had a stable neurological state over
the observed treatment period. This overall downhill
course is consistent with the report of Shapiro et al. in a
large trial of miglustat over a similar time interval in
LOTS patients [18].
Several confounders may be related to the absence of
clearly discernible neuropsychiatric benefits seen with
PMT in LOTS despite some rise in peripherally mea-
sured lymphocyte HexA activity. Pre-trial neurological
impairment may have been too advanced at the onset of
the trial. This interpretation is supported by the finding
that the single subject exhibiting disease stability through-
out the trial period was also the youngest and healthiest
patient in this cohort. Additionally, the induced rise in
HexA may have been insufficient in terms of maximal
achieved activity level and/or the duration of the attained
increase. Further, whereas lymphocyte HexA activity may
correlate, to some extent, with brain HexA activity, it is
unlikely to accurately reflect the CNS enzyme function or
dysfunction. Lymphocytes are short living cells and their
exposure time to PMT is much shorter than that of
the neurons positioned permanently in the brain. In-
deed, in one study in human subjects receiving PMT and
subjected to neurosurgical procedures, the ratio of brain
parenchymal-to-serum PMT concentrations was 2.5 to 5
[6]. Additionally, PMT is a rather lipophylic drug, with
prolonged half-life in humans (t1/2 = 96 hours) [6]. PMT
storage in the lipophylic brain tissue may provide a con-
tinuous local source of the drug, which could eventually
induce inhibition of HexA activity in neurons, in a time-
table which is not necessarily reflected in peripherally
measured enzyme activity. Therefore, the possibility that
even a low dose PMT can partially or transiently inhibit
CNS HexA can be neither excluded nor substantiated by
the present means of follow up. We cannot eliminate the
possibility that a small treatment effect might not have
been detected, due to the obvious limitations of this study,
including the small number of patients studied, the open-
label design of the trial and the variability in the HexA re-
sponse. The difficulty of assessing the slowly progressive
clinical course in LOTS is also complicated by swings of
mood which effect clinical evaluation [2]. An important
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had the same genotypic makeup, it is still possible that
PMTcould do better in other genetic LOTS variants.
In the present report we assessed HexA activity using
a standard assay utilizing a synthetic substrate (MUGS).
While generally reliable, this widely used assay has sev-
eral inherent limitations which could have affected the
measurements in the present study. First, PMT concen-
tration in the actual assay is likely to have been diluted
in the course of the preparatory phases of lymphocyte
isolation. Second, the assay’s pH is higher than would be
expected in the lysosomes, the site of HexA activity in
intact cells in vivo. Third, HexA activity as assessed by
MUGS can reflect both HexA and HexS activity, as their
abundance can be increased by PMT in Tay Sachs cells,
including cells carrying the G269S nutation [9].
Finally, although pharmacological chaperones may
comprise promising therapeutic tools in lysosomal dis-
eases, the present report is not the only example of lim-
ited success in their application. Disappointing results
were also seen in a phase 2 trial with the pharmaco-
logical chaperone Plicera (afegostat tartrate) in the treat-
ment of type 1 Gaucher disease: whereas all patients
enrolled in this study experienced an increase in the
level of the target enzyme glucocerebrosidase as mea-
sured in white blood cells, clinically meaningful im-
provement was recorded in just one out of the eighteen
patients completing who completed the study [19].
Conclusion
As assessed by enzyme activity in peripheral lympho-
cytes, low PMT doses administered in a cyclic manner
dictated by monitoring of lymphocyte HexA activity can
lead to increase this enzyme’s function in LOTS patients
for a period of several weeks to months. However, this
trial of PMT in LOTS did not show discernible benefits
of the treatment on the other measured outcomes over
~18 months treatment. These findings do not support
the use of low doses of PMT for treatment of LOTS,
with the potential exception of patients who are still in a
very early stage of their diseases.
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